Edition:
United Kingdom

Ablynx NV (ABLX.BR)

ABLX.BR on Brussels Stock Exchange

44.64EUR
20 Apr 2018
Change (% chg)

€0.02 (+0.04%)
Prev Close
€44.62
Open
€44.62
Day's High
€44.64
Day's Low
€44.56
Volume
76,924
Avg. Vol
615,087
52-wk High
€45.16
52-wk Low
€10.26

Chart for

About

Ablynx NV is a Belgium-based biopharmaceutical company engaged in the development of Nanobodies, proprietary therapeutic proteins based on single-domain antibody fragments, which combine the advantages of conventional antibody drugs with some of the features of small-molecule drugs. Ablynx NV has more than 30 proprietary and... (more)

Overall

Beta: 1.59
Market Cap(Mil.): €987.62
Shares Outstanding(Mil.): 61.42
Dividend: --
Yield (%): --

Financials

  ABLX.BR Industry Sector
P/E (TTM): -- 84.02 32.74
EPS (TTM): -0.81 -- --
ROI: -23.57 1.58 14.38
ROE: -47.81 2.41 16.07

Healthcare group Sanofi to invest 350 million euros in Canada vaccine facility

PARIS French healthcare group Sanofi is investing 350 million euros ($432.4 million) in a Canadian vaccine facility, which the drugmaker said would help it meet growing demand in this area.

12 Apr 2018

Healthcare group Sanofi to invest 350 mln euros in Canada vaccine facility

PARIS, April 12 French healthcare group Sanofi is investing 350 million euros ($432.4 million) in a Canadian vaccine facility, which the drugmaker said would help it meet growing demand in this area.

12 Apr 2018

Novo Nordisk buys blood drug licence to boost anaemic biopharma business

COPENHAGEN Danish drugmaker Novo Nordisk has secured the global licence for U.S. biotech company EpiDestiny's sickle cell disease (SCD) program in a bid to offset declining sales in its biopharmaceutical business.

05 Apr 2018

BRIEF-Ablynx Says Tender Offers By Sanofi To Acquire Co To Commence On April 4

* PREVIOUSLY ANNOUNCED TENDER OFFERS BY SANOFI TO ACQUIRE ABLYNX WILL COMMENCE ON APRIL 4, 2018

29 Mar 2018

BRIEF-Ablynx ‍Announces Topline Results From Phase II Study Of Vobarilizumab

* ‍ANNOUNCES TOPLINE RESULTS FROM PHASE II STUDY OF VOBARILIZUMAB IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS​

26 Mar 2018

BRIEF-Ablynx NV ‍Ablynx Commences Dosing In Its Phase II Study Of Alx-0171 In Hospitalised Japanese Infants With A Rsv Infection​

* ‍ABLYNX COMMENCES DOSING IN ITS PHASE II STUDY OF ALX-0171 IN HOSPITALISED JAPANESE INFANTS WITH A RSV INFECTION​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

02 Mar 2018

BRIEF-Reg-Sanofi Announces Receipt Of Antitrust Clearances In Connection With The Acquisition Of Ablynx

* Sanofi has received clearance from the Federal Cartel Office of Germany in accordance with the Act Against Restraints of Competition, applicable to Sanofi's proposed acquisition of Ablynx NV

01 Mar 2018

BRIEF-Ablynx FY Operating Loss Widens To 54.2‍​ Million Euros

* FY OPERATING LOSS OF EUR 54.2‍​ MILLION VERSUS LOSS OF EUR 28.6 MILLION YEAR AGO

22 Feb 2018

BRIEF-Ablynx Announces Option Exercise By Sanofi To License Two Additional Target Combinations​

* ABLYNX ANNOUNCES OPTION EXERCISE BY SANOFI FOR TWO ADDITIONAL MULTI-SPECIFIC NANOBODY PRODUCT CANDIDATES

16 Feb 2018

In diabetes war, Novo Nordisk aims to break mold with new pill

LONDON After nearly a century building a company worth $125 billion based on injectable drugs, Denmark's Novo Nordisk - the world's biggest insulin maker - wants to prove this year it can transform the diabetes market with a pill.

06 Feb 2018

Earnings vs. Estimates